Skip to Content
Stock Analyst Update

Rumors of Menthol, Nicotine Bans Are Risks, But Not New

We maintain our valuations and wide moat and negative trend ratings for the cigarette makers as reports have surfaced that the Biden administration is considering lowering the nicotine and menthol levels in cigarettes.

Mentioned: , , ,

Tobacco stocks seem likely to move lower today following media reports that the Biden administration is considering lowering the nicotine and menthol levels in cigarettes in the U.S. The introduction of such measures does not form our base-case assumption for the purposes of forecasting cash flows, but it is one of the ESG risks we have identified, and is captured in our bear-case valuations. There is little evidence to suggest the change in administration has increased the probability of these events occurring, so we maintain our valuations and wide moat and negative trend ratings for the cigarette makers with exposure to the U.S. cigarette market: Altria (MO), British American Tobacco (BATS) and (IMB). Negative headlines such as this have spooked investors since 2017, and the tobacco group is undervalued relative to our estimate of intrinsic value. Our picks remain Philip Morris International (PM), whose exposure to the U.S. is limited to a revenue share of its market-leading reduced risk portfolio, and Imperial Brands, which trades at under 10 times forward earnings and pays a dividend yield of 9%.

The threat of a menthol ban has been an overhang for many years, and nicotine level reductions were mooted by hawkish FDA commissioner Scott Gottlieb in 2017. Menthol is a compound added to cigarettes to ease throat irritation caused by cigarette smoke, and is said to attract young and female consumers, as well as African American smokers. Proponents of prohibition argue that it could lower the rate of smoking initiation in these groups. The menthol category represented 29% of the total U.S. market by volume in 2019, according to Euromonitor. Nicotine is in itself of limited harm if consumed in moderate quantities, but as the addictive substance in cigarettes, it suppresses the cessation rate. If it were to be limited in cigarettes to minimally or even non-addictive levels, the secular decline rate on cigarette volumes could accelerate. 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Philip Gorham does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.